Want to see IN:GLAND full AI Analyst Report?
Top Page
Gland Pharma Ltd.
(GLAND)
Select Model
Select Model
Rating:65Neutral
Price Target:
₹3,191.00
▲(34.17% Upside)
Action:Downgraded
Date:08/17/26
The score is driven primarily by solid financial fundamentals—especially a very conservative balance sheet and improving cash flow—tempered by margin volatility. Technically, the stock has strong upward momentum but is overbought, raising near-term risk. Valuation is the main drag, with a high P/E and low dividend yield requiring continued strong execution to justify.
Positive Factors
Sterile Injectables and CDMO Platform
A sterile-injectables platform serving pharmaceutical partners can support recurring B2B relationships, manufacturing scale, and regulatory know-how. Complex products and integrated development services may also improve customer retention and create longer-term supply opportunities.
Negative Factors
Gross Margin Volatility
The sharp gross-margin decline raises concerns about product mix, pricing, costs, or manufacturing efficiency. Unless margins stabilize, revenue growth may translate inconsistently into earnings and reduce confidence in the durability of profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Sterile Injectables and CDMO Platform
A sterile-injectables platform serving pharmaceutical partners can support recurring B2B relationships, manufacturing scale, and regulatory know-how. Complex products and integrated development services may also improve customer retention and create longer-term supply opportunities.
Read all positive factors
Gland Pharma Ltd. (GLAND) vs. iShares MSCI India ETF (INDA)
Market Cap
₹482.15B
Dividend Yield0.69%
Average Volume (3M)443.60K
Price to Earnings (P/E)42.3
Beta (1Y)0.70
Revenue Growth17.57%
EPS Growth46.53%
CountryIN
Employees4,332
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)68.51
Shares Outstanding164,966,660
10 Day Avg. Volume1,158,304
30 Day Avg. Volume443,597
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)2.70
Price to Sales (P/S)4.35
P/FCF Ratio37.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹3,350.00Price Target Upside40.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)81.33
Revenue Forecast (FY)₹74.50B
Gland Pharma Ltd. Business Overview & Revenue Model
Company Description
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutica...
How the Company Makes Money
Gland Pharma makes money primarily by manufacturing and supplying sterile injectable pharmaceutical products to other pharmaceutical companies and healthcare product marketers. Its core revenue streams typically include: (1) Contract development a...
Gland Pharma Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
88
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 67.25B | 64.31B | 56.17B | 56.65B | 36.25B | 44.01B |
| Gross Profit | 20.67B | 19.32B | 31.54B | 31.11B | 17.65B | 21.51B |
| EBITDA | 19.86B | 19.22B | 12.31B | 12.97B | 10.31B | 15.10B |
| Net Income | 11.29B | 10.27B | 6.99B | 7.72B | 7.81B | 12.12B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 125.11B | 112.25B | 106.61B | 87.78B | 78.34B |
| Cash, Cash Equivalents and Short-Term Investments | 33.59B | 34.33B | 29.52B | 19.39B | 37.63B | 32.43B |
| Total Debt | 0.00 | 2.84B | 3.14B | 3.72B | 44.53M | 47.43M |
| Total Liabilities | -103.58B | 21.53B | 20.74B | 19.37B | 8.19B | 6.76B |
| Stockholders Equity | 103.58B | 103.58B | 91.51B | 87.24B | 79.59B | 71.58B |
Cash Flow | ||||||
| Free Cash Flow | 3.99B | 7.41B | 5.30B | 6.07B | 1.41B | 2.69B |
| Operating Cash Flow | 5.93B | 12.31B | 9.15B | 9.97B | 3.64B | 7.91B |
| Investing Cash Flow | -923.82M | -945.34M | 17.05B | -17.57B | 12.08B | -10.03B |
| Financing Cash Flow | -3.79B | -3.85B | -4.33B | -7.99B | 149.19M | 348.98M |
Gland Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹543.69B | 34.38 | ― | 2.05% | 6.29% | 11.18% | |
73 Outperform | ₹1.10T | 32.37 | ― | 2.13% | 1.85% | -37.51% | |
70 Outperform | ₹148.77B | 27.42 | ― | 0.29% | 19.59% | 47.58% | |
68 Neutral | ₹480.64B | 44.71 | ― | 2.02% | 5.75% | 12.41% | |
67 Neutral | ₹185.83B | 25.15 | ― | 1.86% | 10.69% | -9.09% | |
65 Neutral | ₹482.15B | 42.26 | ― | 0.69% | 17.57% | 46.53% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:GLAND
Gland Pharma Ltd.
2,880.45
874.33
43.58%
IN:ABBOTINDIA
Abbott India Limited
26,143.35
-4,115.29
-13.60%
IN:CIPLA
Cipla Ltd
1,361.00
-182.76
-11.84%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,814.10
143.44
5.37%
IN:MARKSANS
Marksans Pharma Limited
312.40
136.78
77.89%
IN:PFIZER
PFIZER LIMITED
4,041.35
-1,015.17
-20.08%
Gland Pharma Ltd. Corporate Events
Gland Pharma Posts Q1 FY27 Earnings Call Recording Online
Aug 10, 2026
Gland Pharma Ltd. has notified the stock exchanges that it held its earnings call for the quarter ended June 30, 2026, on August 10, 2026, at 18:30 IST. The company has made the audio recording of this earnings call available to investors and the ...
Gland Pharma files FY26 Business Responsibility and Sustainability Report
Jul 31, 2026
Gland Pharma Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26 to the BSE and NSE in compliance with SEBI’s Regulation 34(2)(f). The BRSR, prepared on a standalone basis and assured by...
Gland Pharma Sets 48th AGM, Announces Dividend and KYC Update Drive
Jul 31, 2026
Gland Pharma Limited has scheduled its 48th Annual General Meeting for August 25, 2026, to be held via video conferencing and other audio-visual means, and has made the FY 2025-26 annual report accessible online through a dedicated web link and QR...
Gland Pharma Schedules Q1 FY27 Earnings Call for August 10
Jul 24, 2026
Gland Pharma Limited has scheduled an earnings conference call with investors and analysts on August 10, 2026, at 18:30 IST to discuss its financial performance and business updates for the quarter ended June 30, 2026. Management will present the ...
Gland Pharma Schedules Analyst and Institutional Investor Meetings
Jun 22, 2026
Gland Pharma Ltd. has notified stock exchanges that it will hold one-on-one meetings with Ambit PMS, arranged by BK and 360One, on June 25, 2026. The engagement is part of its regular analyst and institutional investor outreach under Indian listin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.